Alcohol use disorder (AUD) is overrepresented within the United States. Naltrexone, a recommended treatment for AUD, is underutilized. However, the prescribing behaviors of advanced practice registered nurses (APRNs) regarding naltrexone for AUD patients have not been studied. The purpose of our study was to explore the prescriptive practices of a sample of APRNs.
Aims:
To describe and analyze survey responses of a sample of Ohio APRNs with training in medication for addiction treatment (MAT) for substance use disorders (as evidenced by DEA x-waiver receipt) regarding prescribing practices of naltrexone for AUD patients.
Method:
Public information collected from the first author’s Nursing Board (list of APRNs in Ohio) was checked against the public information of x-waivered providers nationally from the Substance Abuse and Mental Health Services Administration’s (SAMHSA) website. This generated a potential sample size of 824 APRNs, all of whom were sent email solicitations to complete a Qualtrics survey. After 3 weeks, 55 surveys were completed, and the data were analyzed. Descriptive statistics were generated as well as a logistic regression with five potential predictor variables against the outcome variable (defined as use of naltrexone for AUD patients).
Results:
Years practicing as an APRN was found to negatively predict naltrexone prescribing behavior for AUD patients. Practice setting and work experience with an addiction specialist physician were not found to predict naltrexone prescribing behavior for AUD patients.
Conclusion:
Implications for further study were discussed, with emphasis on regulatory variance between states.
American Association for Public Opinion Research. (2016). Standard definitions: Final dispositions of case codes and outcome rates for surveys (9th ed.).
3.
AntonR. F.O’MalleyS. S.CirauloD. A.CislerR. A.CouperD.DonovanD. M.GastfriendD. R.HoskingH. D.JohnsonB. A.LoCastroJ. S.LongabaughR.MasonB. J.MattsonM. E.MillerW. R.PettinatiH. M.RandallC. L.SwiftR.WeissR. D.WilliamsL. D.ZwebenA. (2006). Combined pharmacotherapies and behavioral interventions for alcohol dependence: The COMBINE study: A randomized controlled trial. Journal of the American Medical Association, 295, 2003–2017.
BernellS.HowardS. W. (2016). Use your words carefully: What is a chronic disease?Frontiers in Public Health, 4, Article 159. https://doi.org/10.3389/fpubh.2016.00159
6.
BlumenbergC.BarrosA. J. D. (2018). Response rate differences between web and alternative data collection methods for public health research A systematic review of the literature. International Journal of Public Health, 63, 765–773. https://doi.org/10.1007/s00038-018-1108-4
7.
BoseJ.HeddenS. L.LipariR. N.Park-LeeE. (2018). Key substance use and mental health indicators in the United States: Results from the 2017 national survey on drug use and health (Report number HHSS283201300001C). Substance Abuse and Mental Health Services Administration.
8.
BouzaC.AngelesM.AnaM.MariaA. J. (2004). Efficacy and safety of oral Naltrexone and acamprosate in the treatment of alcohol dependence: A systematic review. Addiction, 99, 811–828.
Clearinghouse for Military Family Readiness. (2016). Survey response rates: Rapid literature review. Clearinghouse for Military Family Readiness.
11.
EbertJ. F.HuibersL.ChristensenB.ChristensenM. B. (2018). Paper- or web-based questionnaire invitations as a method for data collections: Cross-sectional comparative study of differences in response rate, completeness of data, and financial cost. Journal of Medical Internet Research, 20(1), e24. https://doi.org/10.2196/JMIR.8353
12.
HarrisA. H.EllerbeL.ReederR. N.BoweT.HagedornH.LembkeA.GordonA. J.OlivaE.KivlahanD.TraftonJ. A. (2013). Pharmacotherapy for alcohol dependence: Perceived treatment barriers and action strategies among Veterans Health Administration service providers. Psychological Services, 10, 410–419.
13.
HarrisA. H.OlivaE.BoweT.HumphreysK. N.KivlahanD. R.TraftonJ. A. (2012). Pharmacotherapy of alcohol use disorders by the Veterans Health Administration: Patterns of receipt and persistence. Psychiatric Services, 63, 679–685.
14.
Henry-EdwardsS.HumeniukR.AliR.MonteiroM.PoznyakV. (2003). Brief intervention for substance use: A manual for use in primary care (Unpublished draft version 1.1 for field testing).
15.
HolzbachR.StammenG.KirchhofU.ScherbaumN. (2019). The prescription of anticraving medication and its economic consequences. European Addiction Research, 25, 224–228.
16.
IheanachoT.IssaM.MarienfeldC.RosenheckR. (2013). Use of naltrexone for alcohol use disorders in the Veterans’ Health Administration: A national study. Drug and Alcohol Dependence, 132, 122–126. https://doi.org/10.1016/j.drugalcdep.2013.01.016
17.
JaliliM.NiroomandM.HadavandF.ZeinaliK.FotouhiA. (2021). Burnout among Healthcare professionals during COVID-19 pandemic: A cross-sectional study. International Archives of Occupational and Environmental Health, 94, 1345–1352.
18.
JonasD. E.AmickH. R.FeltnerC.BobashevG.ThomasK.WinesR.KimM. M.ShanahanE.GassC. E.RoweC. J.GarbuttJ. C. (2014). Pharmacotherapy for adults with alcohol use disorders in outpatient settings: A systematic review and meta-analysis. Journal of the American Medical Association, 311, 1889–1900.
19.
MannK.BatraA.Fauth-BuhlerM.HochE., & the Guideline Group. (2017). German guidelines on screening, diagnosis and treatment of alcohol use disorders. European Addiction Research, 23, 45–60. https://doi.org/10.1159/000455841
20.
MarkT. L.KranzlerH. R.PooleV. H.HagenC. A.McLeodC.CrosseS. (2003). Barriers to the use of medications to treat alcoholism. The American Journal on Addictions, 12, 281–294. https://doi.org/10.1080/10550490390226879
21.
MarkT. L.KranzlerH. R.SongX. (2003). Understanding U.S. addiction physicians’ low rate of naltrexone prescription. Drug and Alcohol Dependence, 71, 219–228. https://doi.org/10.1016/S0376-8716(03)00134-0
22.
MarkT. L.SwaitJ. (2003). Using stated preference modeling to forecast the effect of medication attributes on prescriptions of alcoholism medications. Value in Health, 6, 474–482.
23.
MillerP. M.BookS. W.StewartS. H. (2011). Medical treatment of alcohol dependence: A systematic review. International Journal of Psychiatry in Medicine, 42(3), 227–266.
24.
MyrickH.KranzlerH. R.CirauloD. A.SaxonA. J.JaffeJ. H. (2014). Medications for use in alcohol rehabilitation. In RiesR. K.FiellinD. A.MilerS. C.SaitzR. (Eds.), The ASAM principles of addiction medicine: 5th edition (pp. 713–726). Wolters Kluwer.
25.
National Institute for Health and Care Excellence. (2011). Alcohol-use disorders: Diagnosis, assessment, and management of harmful drinking (high-risk drinking) and alcohol dependence (NICE Guideline CG115). https://www.nice.org.uk/guidance/cg115
NavarroH. J.ShakeshaftA.DoranC. M.PetrieD. J. (2012). The cost-effectiveness of tailored, postal feedback on general practitioners’ prescribing of pharmacotherapies for alcohol dependence. Drug and Alcohol Dependence, 124, 207–215.
29.
Ohio Board of Nursing. (2019). APRN workforce data summary. (Ohio Board of Nursing Website is completely different and I’m getting 404 error when I try to find this document now. I have the pdf saved, but I can’t find it on the website anymore).
30.
OlivaE. M.MaiselN. C.GordonA. J.HarrisA. H. S. (2011). Barriers to use of pharmacotherapy for addiction disorders and how to overcome them. Current Psychiatry Reports, 13(5), 374–381. https://doi.org/10.1007/s11920-011-0222-2
31.
PearsonC.DuffE. (2019). Beyond brief intervention: Pharmacologic management of alcohol use disorder. The Journal for Nurse Practitioners, 15, 627–630. https://doi.org/10.1016/j.nurpra.2019.05.015
32.
PetrakisI. L.LeslieD.RosencheckR. (2003). Use of naltrexone in the treatment of alcoholism nationally in the Department of Veterans Affairs. Alcoholism: Clinical and Experimental Research, 27(11), 1780–1784. https://doi.org/10.1097/01.ALC.0000095861.43232.19
33.
ProchaskaJ. O.DiClementeC. C.NorcrossJ. C. (1992). In search of how people change: Applications to addictive behaviors. The American Psychologist, 47(9), 1102–1114.
34.
ReusV. I.FochtmannL. J.BuksteinO.EylerA. E.HiltyD. M.Horvitz-LennonM.MahoneyJ.PasicJ.WeaverM.WillsC. D.McIntyreJ.KiddJ.YagerJ.HongS. (2018). The American Psychiatric Association practice guideline for the pharmacological treatment of patients with alcohol use disorder. American Journal of Psychiatry, 175(1), 86–90.
35.
RosnerS.Hackl-HerrwerthA.LeuchtS.VecchiS.SrisurapanontM.SoykaM. (2010). Opioid antagonists for alcohol dependence (Review). Cochrane Database of Systematic Reviews, 12, Article CD001867. https://doi.org/10.1002/14651858.CD001867.pub3
36.
ScherbaumN.HolzbachR.StammenG.KirchofU.BonnetU. (2020). Very low frequency of drug therapy of alcohol dependence in Germany—Analysis of data of a statutory health insurance. Pharmacopsychiatry, 53, 37–39.
37.
SoykaM.LiebM. (2015). Recent developments in pharmacotherapy of alcoholism. Pharmacopsychiatry, 48, 123–135.
38.
SpanagelR.VengelieneV. (2013). New pharmacological treatment strategies for relapse prevention. Current Topics in Behavioral Neurosciences, 13, 583–609. https://doi.org/10.1007/7854_2012_205
39.
SpauldingR.SmithC. E. (2021). How telehealth care exploded due to COVID: What nurse researchers need to know. Research in Nursing and Health, 44(1), 5–8.
40.
SpithoffS.TurnerS.GomesT.MartinsD.SinghS. (2017). First-line medications for alcohol use disorders among public drug plan beneficiaries in Ontario. Canadian Family Physician, 63, 277–283.
41.
Substance Abuse and Mental Health Services Administration. (2009). Treatment Improvement Protocol (TIP) series: TIP 49, Incorporating alcohol pharmacotherapies into medical practice (HHS Publication No. (SMA) 09-4380). U.S. Department of Health and Human Services. https://www.ncbi.nlm.nih.gov/books/NBK64041/pdf/Bookshelf_NBK64041.pdf
ThomasC. P.WallackS. S.LeeS.McCartyD.SwiftR. (2003). Research to practice: Adoption of Naltrexone in alcoholism treatment. Journal of Substance Abuse Treatment, 24, 1–11.
